Vivoryon Therapeutics receives FDA fast track designation for varoglutamstat in early Alzheimer’s disease

Vivoryon Therapeutics

22 December 2021 - 21 – Vivoryon Therapeutics today announced that the U.S. FDA has granted fast track designation for varoglutamstat (PQ912), an investigational oral small molecule medicine for the potential treatment of early Alzheimer’s disease. 

Varoglutamstat is Vivoryon’s lead product candidate and is designed to block formation of N3pE amyloid, a particularly neurotoxic variant of the Abeta peptide, by inhibiting glutaminyl cyclase and its isoenzyme.

Read Vivoryon Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track